XCUR Key Statistics, Chart & Performance
The current stock price of XCUR is 5.99 USD. In the past month the price increased by 55.18%. In the past year, price decreased by -65.93%.
XCUR Latest News, Press Relases and Analysis
XCUR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About XCUR
Company Profile
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The company is headquartered in Chicago, Illinois and currently employs 7 full-time employees. The company went IPO on 2018-05-09. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The firm is also exploring strategic alternatives to maximize stockholder value.
Company Info
EXICURE INC
2430 N. Halsted St.
Chicago ILLINOIS 60614 US
CEO: David A. Giljohann
Employees: 7
Phone: 18476731707
EXICURE INC / XCUR FAQ
Can you describe the business of EXICURE INC?
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The company is headquartered in Chicago, Illinois and currently employs 7 full-time employees. The company went IPO on 2018-05-09. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The firm is also exploring strategic alternatives to maximize stockholder value.
Can you provide the latest stock price for EXICURE INC?
The current stock price of XCUR is 5.99 USD. The price decreased by -0.17% in the last trading session.
What is the dividend status of EXICURE INC?
XCUR does not pay a dividend.
What is the ChartMill rating of EXICURE INC stock?
XCUR has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for XCUR stock?
EXICURE INC (XCUR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.07).
Is EXICURE INC (XCUR) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on XCUR.
XCUR Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to XCUR. When comparing the yearly performance of all stocks, XCUR is a bad performer in the overall market: 70.63% of all stocks are doing better.
XCUR Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to XCUR. XCUR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
XCUR Financial Highlights
Over the last trailing twelve months XCUR reported a non-GAAP Earnings per Share(EPS) of -3.07. The EPS decreased by -35.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -60.45% | ||
| ROE | -133.23% | ||
| Debt/Equity | 0 |